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ABSTRACT: Cornelia de Lange syndrome (CdLS) is cha-
racterized by facial dysmorphism, growth failure, intel-
lectual disability, limb malformations, and multiple organ
involvement. Mutations in five genes, encoding subunits
of the cohesin complex (SMC1A, SMC3, RAD21) and its
regulators (NIPBL, HDAC8), account for at least 70%
of patients with CdLS or CdLS-like phenotypes. To date,
only the clinical features from a single CdLS patient with
SMC3 mutation has been published. Here, we report the
efforts of an international research and clinical collabo-
ration to provide clinical comparison of 16 patients with
CdLS-like features caused by mutations in SMC3. Mode-
ling of the mutation effects on protein structure suggests a
dominant-negative effect on the multimeric cohesin com-
plex. When compared with typical CdLS, many SMC3-
associated phenotypes are also characterized by postnatal
microcephaly but with a less distinctive craniofacial ap-
pearance, a milder prenatal growth retardation that wor-
sens in childhood, few congenital heart defects, and an
absence of limb deficiencies. While most mutations are
unique, two unrelated affected individuals shared the same
mutation but presented with different phenotypes. This
work confirms that de novo SMC3 mutations account for
1%–2% of CdLS-like phenotypes.
Hum Mutat 36:454–462, 2015. C© 2015 Wiley Periodicals, Inc.
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Introduction
Cornelia de Lange syndrome (CdLS; MIMs #122470, #300590,
#610759, #614701, #300882) is a multisystem developmental diag-
nosis characterized by distinctive facial dysmorphism, prenatal and
postnatal growth failure, intellectual disability, limbmalformations,
hypertrichosis, and variable involvement of other organ systems
[Kline et al., 2007]. The prevalence is estimated to be up to one in
15,000 births [Kline et al., 2007]. Almost all cases are sporadic with
de novo heterozygous loss-of-function mutations in NIPBL (MIM
#608667) being the most common genetic finding in typical CdLS
[Gillis et al., 2004; Krantz et al., 2004; Tonkin et al., 2004; Selicorni
et al., 2007; Pie et al., 2010;Wierzba et al., 2012]. A proportion of the
“NIPBL-negative” cases with typical CdLS have recently been shown
to have mosaic NIPBLmutations, often undetected in the blood by
Sanger-based screening [Huisman et al., 2013; Ansari et al., 2014;
Baquero-Montoya et al., 2014; Braunholz et al., 2014]. Mutations
in four other genes have been reported to account for a smaller
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proportion of mostly atypical cases; SMC1A (MIM #300040) on
chromosome Xp11 (4%–6%), SMC3 (MIM #606062) on chro-
mosome 10q25 (<1%), RAD21 (MIM #606462) on chromosome
8q24 (<1%), and HDAC8 (MIM #300269) on chromosome Xq13
(4%) [Musio et al., 2006; Deardorff et al., 2007, 2012a, 2012b; Kaiser
et al., 2014; Minor et al., 2014].
These five genes encode regulatory or structural components of
the evolutionary conserved cohesin complex, which has been impli-
cated in a wide range of functions including sister chromatid cohe-
sion, DNA repair mechanisms, gene regulation, andmaintenance of
genome stability [Revenkova et al., 2009]. Cohesin is a multimeric
complex consisting of an SMC1A–SMC3 heterodimer and the two
non-SMC subunits, RAD21, and a STAGprotein. Each SMCprotein
folds upon itself so that the N- and C-termini meet to form a globu-
lar ATP-binding “head” domain separated from a globular “hinge”
domain by antiparallel coiled-coil segments. SMC3 and SMC1A in-
teract via their respective hinge regions to form a bracelet-shaped
heterodimer (Fig. 1A). The two ATPase head domains further inte-
ract with the N- and C-termini of RAD21, creating a ring structure
that is proposed to encircle sister chromatids [NasmythandHaering,
2009]. NIPBL has been shown to facilitate loading of cohesin onto
chromatin, and HDAC8 is involved in recycling of cohesin after its
removal from chromatin [Deardorff et al., 2012a].
To date, only the clinical features of the unique mildly af-
fected CdLS male with SMC3 mutation has been published
(c.1464 1466del, p.(Glu488del)) [Deardorff et al., 2007; Pie et al.,
2010]. Subsequently, a missense SMC3 mutation has been re-
ported without clinical correlation in one patient within a large
cohort of individuals with autism spectrum disorder (c.2413C>T;
p.(Arg805Cys)) [Sanders et al., 2012] and five additional mutations
in a cohort of typical and atypical CdLS patients [Ansari et al., 2014]
with the detailed clinical descriptions of these cases documented for
the first time in this manuscript.
Here, we report the clinical features of 16 unrelated SMC3 indi-
viduals identified via a large international collaboration and assess
the degree of overlap with typical CdLS associated with this gene.
Of these, 10 are unreported patients with novel or reported muta-
tions in the SMC3 gene and six individuals have only had molecu-
lar information previously published. Furthermore, we mapped all
mutations to the known structure of the SMC complex to predict
molecular/functional consequences.Our results clearly indicate that
SMC3 mutations result in a CdLS-like phenotype and account for




We screened formutations in SMC3 an internationally assembled
cohort of 674 patients with typical CdLS and overlapping clinical
presentations who had no known molecular etiology. All patients
were enrolled in this study under institutionally approved protocols
of informed consent at the Odense University Hospital, University
Hospital “Lozano Blesa” of Zaragoza, The Children’s Hospital of
Philadelphia, the UK (Scotland A) MREC Committee, the MET
Committee at the Academic Medical Centre of the University of
Amsterdam, and University of Lu¨beck. Most individuals in this
study were diagnosed by clinical geneticists due to clinical features
consistent or overlapping with a CdLS phenotype.
Additional cases of mutations in SMC3 were referred from clini-
cal colleagues who identified mutations by the use of different
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Figure 1. A: Schematic representation of the SMC1A-SMC3 heterodimer of the cohesin complex and the locations of SMC3 mutations in coiled-
coil, hinge, and head domains. Position of mutated residues in CdLS patients, described in the text, is indicated by red dots. B: Multiple sequence
alignment of several proteins homologous toSMC3 in the areas surroundingmutated residuesPhe47, Thr235, Arg236, Glu287, Lys400_Ser401, Glu488,
Gly655, Gly666, Leu832_Asn833, Arg 839, His917, Gln1147, and Thr1215. Represented sequences are: Homo sapiens (SMC3_HUMAN), Pongo abelii
(SMC3_PONGO), Rattus norvegicus (SMC3_RAT), Mus musculus (SMC3_MOUSE), Bos taurus (SMC3_BOVIN), Xenopus laevis (SMC3_XENOPUS),
Saccharomyces cerevisiae (SMC3_YEAST), and Plasmodium falciparum (SMC3_PLASMOD). Residues are colored according to conservation. C:
Left: predicted structure of SMC3 head domain in the neighborhood of the ATPase active center. Interaction surface of SMC3 to SMC1A has been
colored according to electrostatic characteristics (red: negative; blue: positive; white: neutral). Positions of ATP, Mg++ atom, and residue Q1147
are indicated. Right: predicted surface for Q1147E mutant. The negatively charged patch that appeared close to gamma phosphate of ATP and in
the interaction surface to SMC1A is highlighted.
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molecular analyses such as gene panel or exome-sequencing ap-
proaches. Most probands ascertained as CdLS were prescreened
and found to be negative for mutations in NIPBL and SMC1A.
Mutation Screening by Sanger Sequencing
Genomic DNA was isolated from peripheral blood leukocytes
using standard protocols. PCR primers flanking the entire coding
region (exons 1–29) and flanking intron sequences of SMC3 gene
were used as previously described [Deardorff et al., 2007; Pie et al.,
2010]. The resulting PCRproductswere sequencedusing theBigDye
Terminator 3.1 reagents on an ABI 3730 analyzer. The SMC3 refer-
ence sequence used was NM 005445.3, in which the A of the ATG
translation initiation codon was nucleotide 1. Parental genotypes
were screened to assess whether the variant was de novo or inhe-
rited when parental DNA was available.
Ion Torrent Semiconductor Gene Panel Sequencing
Mutation analyses by Ion AmpliSeq-Ion PGMwere performed as
described previously [Ansari et al., 2014; Baquero-Montoya et al.,
2014;Braunholz et al., 2014].Briefly, 10–20ngof genomicDNAwere
amplified using custom-designed gene panels (IonAmpliSeq
TM
; Life
Technologies, Darmstadt, Germany) to cover the coding exons of
the known CdLS genes, including approximately 90% of the coding
sequence of SMC3 (NC 000010) and its splice junctions in particu-
lar. The DNA library was sequenced on an Ion PGMTM instrument
(Life Technologies, Darmstadt, Germany). Sequence alignment and
variant callingwere performed as described previously [Ansari et al.,
2014; Baquero-Montoya et al., 2014; Braunholz et al., 2014]. Possible
pathological variants found were assessed by Sanger sequencing.
Exome Sequencing
For P7, exomes were capturedwith the Agilent SureSelect Human
All Exon V4+UTR kit (Agilent Technologies, Santa Clara, CA) and
sequencing was performed on Illumina HiSeq 2000 machines using
standard pair-end read sequencing protocol (Illumina, San Diego,
CA). Analysis was as per Falk et al. 2014 and Li et al. 2014. Possible
pathological variants found were confirmed by Sanger sequencing.
Exome sequencing for P13 was performed clinically at the Baylor
Whole Genome Lab. Briefly, exomes were captured using VCRome
2.1 in-solution capture, and sequenced on IlluminaHiSeq using 100
bppaired-endreads.Data analysis and interpretationwas asperYang
et al. 2013. Possible pathological variants found were confirmed by
Sanger sequencing.
Exome sequencing was performed in the affected individual P14
as well as in the nonaffected parents. Exomes were enriched in so-
lution with SureSelectXT Target Enrichment System (Agilent Tech-
nologies) or SeqCap EZ VCRome 2.0 (Roche NimbleGen, Madison,
WI) and sequenced as 100 bp paired-end runs on a HISeq2000 or
HISeq 2500 system (Illumina).
Mutation Modeling
Three-dimensional models of the HEAD and HINGE do-
mains of the human SMC1A/SMC3 dimer, for wild-type (wt)
and mutant proteins, were generated using homology model-
ing procedures and the coordinates of the mouse HINGE do-
main [Kurze et al., 2011; PDB code: 2WD5] and yeast HEAD
domain -SMC1 homodimer [Haering et al., 2004; PDB code:
1W1W] as templates. Model coordinates were built using the
SWISS-MODEL server [Peitsch, 1996; Guex et al., 1999; Schwede
et al., 2003] available at http://swissmodel.expasy.org/, and their
structural quality was checked using the analysis programs pro-
vided by the same server [Anolea/Gromos/QMEAN4; Benkert
et al., 2011] being within the range of those accepted for
homology-based structure models. To optimize geometries, mo-
dels were energy minimized using the GROMOS 43B1 force
field implemented in DeepView (http://spdbv.vital-it.ch/), using
500 steps of steepest descent minimization followed by 500 steps
of conjugate-gradient minimization. Coiled-coil predictions were
calculated using COILS server with a window of 28 residues
[http://www.ch.embnet.org; Lupas et al., 1991]. Multiple sequence
alignment of proteins from the SMC3 family was generated
using TCOFFEE (http://www.tcoffee.org/) [Notredame et al., 2000].
Functional prediction for nonsynonymous or indel variants were
obtained using PolyPhen-2 (http://genetics.bwh.harvard.edu/pph/)
[Adzhubei et al., 2010], SIFT (http://sift.jcvi.org/) [Ng andHenikoff,
2001], PROVEAN (http://provean.jcvi.org/index.php) [Choi et al.,
2012], Mutation Taster (http://www.mutationtaster.org/) [Schwarz
et al., 2010], and the Biomol-Informatics exome analysis system
(http://results.genoma4u.com/).
Reference Sequences
SMC3 accession numbers used include NM 005445.3 (mRNA)
and NP 005436.1 (RefSeq protein). SMC3 protein sequences
(UniProt) for human (Q9UQE7), Pongo abelii (Q5R4K5), Rattus
norvegicus (P97690), Mus musculus (Q9CW03), Bos taurus
(O97594), Xenopus laevis (O93309), Saccharomyces cerevisiae
(P47037), and Plasmodium falciparum (Q8I1U7).
Results
Intragenic Mutations in SMC3 in a Large Cohort of Patients
Sequence analysis of patients with CdLS and CdLS-like pheno-
types for mutations in SMC3 identified 15 different intragenic mu-
tations in 16 unrelated individuals. Six of 15 mutations have been
previously described [Deardorff et al., 2007; Ansari et al., 2014];
therefore, here we report 10 individuals with nine new mutations
(Table 1). Seven of the 10 individuals had both parents available
for testing and in each case these mutations occurred de novo.
One in-frame de novo deletion of three nucleotides (c.1464 1466del;
p.(Glu488del)) was also identified in the first reported individual
[Deardorff et al., 2007]. Three of these are caused by in-frame mu-
tations that retain the open-reading frame (one duplication and two
deletions of one or two residues) and sevenmutationsweremissense
(Table 1; Fig. 1; Supp. Fig. S1). All variants have been added to a
publicly accessible LOVD database (http://www.LOVD.nl/SMC3).
None of these mutations were seen in 100 control alleles or publicly
available repositories of sequence variation.
In Silico Analyses of Missense and In-Frame Mutations
The predicted functional effect of each mutation is summarized
in Table 1 and the cross-species alignment showing the degree of
evolutionary conservation of the residues involved in the missense
and in-frame variants is shown in Figure 1B. Figure 1A indicates
the location of each variant with regard to the known functional
domains of SMC3.
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Table 1. SMC3Mutations Identified
ID Mutation De novo Exon Predicted protein change Protein domain In silico functional prediction Reference
SIFT/Provean PolyPhen-2
1 c.139T>C n/a 4 p.(Phe47Leu) Head Damaging: 0.01 Probably damaging: 1 Ansari et al. 2014
2 c.[ = /703 705del] mosaic + 9 p.[ = /Thr235del] Coiled coil Deleterious: –10.683 n/a Ansari et al. 2014
3 c.707G>C + 9 p.(Arg236Pro) Coiled coil Damaging: 0.04 Probably damaging: 0.998 This study
4 c.859 861dup n/a 11 p.(Glu287dup) Coiled coil Deleterious: –9.076 n/a This study
5 c.1200 1202delGTC n/a 13 p.(Lys400 Ser401delinsAsn) Coiled coil Deleterious: –13.196 n/a Ansari et al. 2014
6 c.1464 1466delAGA + 15 p.(Glu488del) Coiled coil Deleterious: –8.108 n/a Deardorff et al. 2007
7 c.1464 1466delAGA + 15 p.(Glu488del) Coiled coil Deleterious: –8.108 n/a This study
8 c.1462G>A + 15 p.(Glu488Lys) Coiled coil Tolerated: 0.2 Possibly damaging: 0.851 This study
9 c.1561C>T n/a 16 p.(Arg521∗) Hinge n/a n/a Ansari et al. 2014
10 c.1964G>A + 19 p.(Gly655Asp) Hinge Damaging: 0 Probably damaging: 1 This study
11 c.1997G>C + 19 p.(Gly666Ala) Hinge Damaging: 0.01 Probably damaging: 1 This study
12 c.2494 2499del + 22 p.(Leu832 Asn833del) Coiled coil Deleterious: –11.538 n/a This study
13 c.2515C>T n/a 22 p.(Arg839Cys) Coiled coil Damaging: 0.01 Probably damaging: 1 This study
14 c.2750A>C + 24 p.(His917Pro) Coiled coil Tolerated: 0.08 Possibly damaging: 0.820 This study
15 c.3439C>G + 27 p.(Gln1147Glu) Head Damaging: 0 Probably damaging: 0.998 Ansari et al. 2014
16 c.3644C>T n/a 29 p.(Thr1215Ile) Head Damaging: 0 Probably damaging: 1 This study
The on-line predicted functional effect of nonsynonymous or indel variants has been determined by SIFT or Provean programs, respectively. The SMC3 reference sequence used
was NM_005445.3, in which the A of the ATG translation initiation codon was nucleotide 1.
Gly655 localizes to the SMC3 hinge domain and the substitution
with aspartic acid is predicted to structurally destabilize the domain
core. Thr235, Arg236, Arg839, and His917 localize to the N- and
theC-terminal coiled-coil structures, respectively, and their deletion
or substitution is predicted to displace the two antiparallel helices
(Supp. Fig. S2).
In the globular ATP-binding head domain Phe47 is located in the
alpha helices. Gln1147 is within the functional motif D-loop, close
to both the gamma-phosphate of ATP and the interface between
the head domains of SMC3 and SMC1A. Substitution of this polar
residue Gln1147 by a negatively charged glutamate residue could
alter the ATPase activity of the active site of the heterodimer as
well as alter the essential interaction between SMC1A and SMC3
at the head interface (Fig. 1C). Thr1215 is located in an apparently
nonstructured region close to the C-terminus and the effect of the
isoleucine substitution at this residue is not clear, although it cannot
be excluded a putative role in the SMC3–RAD21 interaction.
Clinical Features of Individuals with SMC3Mutations
The clinical features in the 16 individuals with mutations invol-
ving SMC3 are summarized in Table 2 and Supp. Table S1. Figure
2 shows facial and limb findings. Many patients have CdLS-like
craniofacial features including brachycephaly (73%, [11/15]), low
anterior hairline (50%, [7/14]), arched eyebrows (93%, [14/15]),
synophrys (73%, [11/15]), long eyelashes (94%, [15/16]), ptosis
(27%, [4/15]), depressed nasal bridge (47%, [7/15]), anteverted
nostrils (57%, [8/14]), long philtrum (67%, [10/15]), thin upper lip
vermilion (81%, [13/16]), downturned corners of the mouth (60%,
[9/15]), high palate (45%, [5/11]), dental anomalies (38%, [5/13]),
and micrognathia (40%, [6/15]) (Table 2). Although often long,
the philtrum is typically not smooth in these individuals and only
one patient had a cleft palate. Major limb malformations were not
observed. Intellectual disability was a prominent feature, although
behavioral problems were not frequently reported and many were
described as having friendly personalities.
Discussion
To further characterize the nature of SMC3 gene mutations and
the range of resulting clinical features, we utilized an international
cooperative research and clinical effort coupled with standard se-
quencing and next-generation sequencing strategies. This enabled
us to identify 16 probands with 15 different intragenic mutations
in SMC3, including the previously reported individuals [Deardorff
et al., 2007; Ansari et al., 2014]. Based on these numbers, we could
estimate that individuals with SMC3mutations comprise1%–2%
of patients with features suggestive of CdLS or overlapping pheno-
types.
Typically, SMC3 mutations identified in these CdLS-like patients
are missense or in-frame insertions or deletions, similar to CdLS-
causing mutations found in the SMC1A protein [Musio et al., 2006;
Deardorff et al., 2007; Liu et al., 2009; Revenkova et al., 2009; Man-
nini et al., 2010;Gimigliano et al., 2012].Nineof 15SMC3mutations
identified predict amino acid alterations in the coiled-coil domain
(Fig. 1A; Supp. Fig. S2). In the SMC1A-associated CdLS-like disor-
der, 69% of the disease-causing mutations (all missense/in-frame)
are also identified in the cognate coiled-coil domain [Gervasini et al.,
2013). The similarity of structure and function of the two SMC
proteins, as well as the mutation spectrum, suggests that SMC3
missense/in-frame mutations may act via a dominant-negative ef-
fect as has been previously suggested for other mutations in the
SMC1A protein [Deardorff et al., 2007; Mannini et al., 2013].
Several craniofacial features commonly seen in typical CdLS
(>80% of the CdLS patients; reviewed in [Kline et al., 2007]) are
absent or infrequent in this SMC3 cohort. For example, while the
eyebrows may be highly arched and the eyelashes long, synophrys is
often absent or subtle. The nasal bridge is less frequently depressed,
and the nasal tip is often broad or bulbous, unlike the small trian-
gular shaped nose in typical CdLS. Furthermore, the nostrils are
not typically anteverted in this cohort, as is seen in CdLS caused by
mutations in NIPBL [Rohatgi et al., 2010]. The philtrum may be
long but is often well formed in this cohort and infrequently flat,
as in typical CdLS. Thin upper lips vermilion are observed but the
downturned mouth often seen in typical CdLS is uncommon.
Congenital heart defects are common in CdLS (13%–70%) with
isolated defects seen in 86% (PS, VSD, and ASD) and multi-
ple defects in 14% [Selicorni et al., 2009]. Consistent with this,
SMC3 probands appear to have cardiac malformations (56%). For
example, anumberof individualspresentedwith somedegreeofpul-
monic stenosis, one of themost frequent findings in CdLS [Selicorni
et al., 2009; Chatfield et al., 2012]. In addition, two individuals
showed with aortic stenosis with bicuspid aortic valve and one with
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Figure 2. Clinical photographs of individuals with SMC3 mutations. Photos for individual patients are grouped ([i–iv] frontal view at different
ages, hands, and feet, when they are available) and labeled with corresponding identifier, mutation, and sex; ♂ = male,♀ = female.
Tetralogy of Fallot. While this frequency and severity of cardiac
anomalies can be seen in CdLS caused by mutations inNIPBL, they
are infrequent in patients with SMC1A mutations [Chatfield et al.,
2012], suggesting that SMC3 is important for the normal develop-
ment of the heart.
Clinical comparison between two individuals (P6 and P7) that
carried the same deletion of three nucleotides, c.1464 1466del
[Deardorff et al., 2007], showed a similar craniofacial appearance
during their newborn period, even though this evolved with time
differently (Fig. 2). In addition, these patients had markedly diffe-
rent cognitive and developmental impairment and musculoskeletal
involvement, with one working as an adult and the other nonver-
bal and nonambulatory (Fig. 2; Supp. Table S1). This emphasizes
that phenotypes associated with the identical mutations are likely
variable, which indicates the influence of other factors in the mani-
festation of CdLS, as it has been reported for other CdLS genes
[Gillis et al., 2004; Pie et al., 2010].
In general, SMC3 probands present with a mild to severe phe-
notype that differs from typical CdLS that is frequently caused by
NIPBL mutations. Clinical features of patients with SMC3 muta-
tions aremore similar to those of patients withmutations in SMC1A
[Musio et al., 2006; Borck et al., 2007; Deardorff et al., 2007; Liu
et al., 2009; Mannini et al., 2010; Gervasini et al., 2013]. Thus, the
craniofacial phenotype of patients with mutations in SMC1A and
SMC3 genes do show overlapping features such as broader, fuller
less arched eyebrows, and amore prominent nasal bridge [Deardorff
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Table 2. Frequency of Clinical Features in Individuals with SMC3Mutations Compared with Classical CdLS
Category Feature Frequency in SMC3 percent SMC3 details (number of
classical CdLSa (#observed/#assessed) patients with finding)
Craniofacial
findings
Head Brachycephaly 73% (11/15)
Low anterior hairline 92% 50% (7/14)
Skull Congenital (5) and/or postnatal (12) microcephaly,
plagiocephaly (1), flat facies (1), facial asymmetry
(1), frontal bossing (1), posterior hair whorl on left
side (1), sparse temporal hair (1), delayed closure
of anterior fontanelle (1).
Eyes Arched eyebrows 93% (14/15)
Synophrys 99% 73% (11/15)
Thick eyebrows 69% (9/13)
Long eyelashes 99% 94% (15/16)
Hooding of lids 15% (2/13)
Nose Depressed nasal bridge 83% 47% (7/15)
Anteverted nostrils 88% 57% (8/14)
Long and/or featureless philtrum 94% 67% (10/15)
Broad/bulbous nasal tip 86% (12/14)
Mouth Thin upper lip vermilion 94% 81% (13/16)
Downturned corners of mouth 94% 60% (9/15)
Palate: high 86% 45% (5/11)
Palate: cleft 20% 7% (1/14)
Small/widely spaced teeth 86% 22% (2/9)
Dental anomalies 38% (5/13) Delayed with irregular eruption (1), not secondary
(1), dysmorphic teeth (1), pegged incisors (1).
Micrognathia/retrognathia 84% 40% (6/15)
Neck Short neck 46% (6/13)
Other facial Lateral extension eyebrows (1), almond shaped (1),
deep-set eyes (1). Prominent supraorbital ridges
(1). Low-set ears (6), posteriorly rotated ears (3),
large ears (2). Small mouth (1), prognathism (2).
Low posterior hairline (2), webbed neck (1).
Musculoskeletal
system
Hands Small hands 93% 79% (11/14)
Proximally set thumbs 72% 75% (12/16)
Short first metacarpal 79% (11/14)
Clinodactyly fifth finger 74% 64% (9/14)
Short fifth finger 69% (9/13)
Single palmar crease 51% 36% (5/14)
Feet Small feet 93% 85% (11/13)
Syndactyly of toes 86% 29% (4/14)
Arms Restriction of elbow movements 64% 45% (5/11)
Other skeletal Tapered fingers (2), syndactyly 2nd–3rd (1) and
3rd–4th (1) fingers, hyoplastic distal phalanges (1).
Joint laxity with flexible fingers (1). Madelung
deformity (1). Tapered 1st toes, short 4th metatarsal
(1), gap between 1st and 2nd toes (1), pes cavus (2),
and metatarsus adductus (1). Pectus excavatum
(1), short sternum (1), scoliosis (1), cleft and
butterfly vertebrae (1), Klippel-Feil (1). Dysplastic
hip (1). Sacral dimple (1). Leg length discrepancy
(1). Delayed skeletal maturity (1) and decreased
muscle bulk (1). Extension defect of Achilles
tendon (1). Bunions (1).
Cardiac system Cardiac defects 13%–70% 56% (9/16) PDA+ASD (1), PS+VSD (1), ASD+ AS+BAV (1), ASD
(PFO) (1), pulmonary artery dysplasia (1),
PS+AS+BAV (1), PPS (1), ASD+VSD (1),
TOF+PS+main pulmonary artery hypoplasia (1).
Gastrointestinal
system
GERD 65% 67% (10/15)
Feeding problems in infancy 79% (11/14)





Genitourinary defects 40%–57% 40% (6/15) Amenorrhea (1), cryptorchidism (2), hypoplastic
genitalia (1), inguinal hernia (2). Bilateral
megaureter (1), VUR (2), small kidneys (1).
ENT Hearing loss 60% 54% (7/13)
Ophthalmic system Ptosis 44%–46% 27% (4/15)
Myopia 57%–58% 45% (5/11)
Lacrimal duct obstruction 33% (4/12)
(Continued)
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Table 2. Continued
Category Feature Frequency in SMC3 percent SMC3 details (number of
classical CdLSa (#observed/#assessed) patients with finding)
Other Upward deviation of gaze + amblyopia (1),
astigmatism (1), exotropia (1), esotropia + cortical
visual impairment + sensitivity to light
(photophobic) (1), exotropia + astigmatism (1),
microphthalmia, Peter’s anomaly, congenital
cataracts, and glaucoma (1).
Skin Cutis marmorata 60% 31% (4/13)
Hirsutism 78% 93% (14/15)
Nevus flameus 8% (1/12)




CNS anomalies 36% (4/11) Porencephalic cyst (1). The absence of the splenium
of the corpus callosum, a large septum cavum
pellucidum and cavum verge (1). Mildly coarse
gyral pattern (1). Very small corpus callosum, cysts
of right frontal region (1).
Seizures 23% 25% (3/12)
Other Hypertonia (1), hypotonia (3), autonomic
dysfunction: apnea, bradycardia, temperature
instability.
Intellectual disability 100% (13/13)
Behavior, personality Friendly (6), sociable (3), extremely active (1),
affectionate (1), fussy (1), interactive (2), decreased
eye contact (1), attention deficit disorder (1),
autistic-like features (1), autism (1), aggression (2)
and Self-injurious behavior (2), Shy (1).
aThese frequencies in classical CdLS of these clinical features are compiled from different sources [Jackson et al. 1993; Kaga et al., 1995; Luzzani et al., 2003; Wygnanski-Jaffe et al.,
2005; Nallasamy et al., 2006; Kline et al., 2007; Selicorni et al., 2009; Chatfield et al., 2012].
Clinical features are summarized by category. For the classical CdLS feature frequencies, percent frequencies are noted. For SMC3 features, percentages are noted and in parentheses,
fractional data. In the comments column, single numbers in parentheses indicate the number of subjects noted with the feature.
ENT, ear-nose-throat; GERD, gastroesophageal reflux disease; CNS, central nervous system; PDA, patent ductus arteriosus; ASD, atrial septal defect; PS, pulmonary stenosis,
VSD, ventricular septal defect, PFO, patent foramen ovale; AS, aortic stenosis; BAV, bicuspid aortic valve; PPS, peripheral pulmonic stenosis; TOF, tetralogy of Fallot, VUR,
vesicoureteral reflux.
et al., 2007; Rohatgi et al., 2010]. In addition, both groups of pa-
tients seem to have less growth restriction than typically seen in
patients with mutations in NIPBL. However, this is fairly difficult
to generalize, given the variability in the range of severity and the
small number of patients with SMC3mutations.
Interestingly, several individuals from this cohort were ascer-
tained independently of a diagnosis of CdLS (e.g., P7 and P13).
Although they have some CdLS-overlapping features, they were felt
to be divergent enough from CdLS to pursue exome-based testing
rather than CdLS gene panel testing. In addition, an SMC3 muta-
tion has been reported in a patient with autism spectrum disorder,
but to our knowledge has no obvious CdLS phenotype [Sanders
et al., 2012]. These findings are consistent with an emerging range
of clinical phenotypes caused by mutations in the cohesin complex,
as is supported by the finding of an HDAC8 mutation in a fami-
ly with Wilson–Turner syndrome (intellectual disability, truncal
obesity, hypogonadism, and distinctive facial features) [Harakalova
et al., 2012] and an SGOL1mutation in 17 patients with CAID syn-
drome (chronic atrial and intestinal dysrhythmia) [Chetaille et al.,
2014]. These findings indicate that the range of clinical phenotypes
caused by alterations in cohesin may be significantly broader than
previously appreciated.
Conclusion
We report a series of SMC3 mutations that provide a significant
advance in our understanding of the clinical and molecular basis of
human disorders of cohesin. Although this cohort represents1%–
2%of individuals with CdLS-like phenotypes, they provide us novel
insight into the understanding of cohesin in health and disease.
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